Related Experiment Video
Updated: Dec 18, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly
David M Chascsa1, Elise M N Ferré2, Yannis Hadjiyannis2
1TranslationalHepatology SectionLiver Diseases BranchNational Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthBethesdaMD.
Background And Aims:
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), caused by autoimmune regulator (AIRE) mutations, manifests with chronic mucocutaneous candidiasis (CMC) and multisystem autoimmunity, most often hypoparathyroidism (HP) and adrenal insufficiency (AI). European cohorts previously reported a ~10% prevalence of APECED-associated hepatitis (APAH) with presentations ranging from asymptomatic laboratory derangements to fatal fulminant hepatic failure. Herein, we characterized APAH in a large APECED cohort from the Americas.
Approach And Results:
Forty-five consecutive patients with APECED were evaluated (2013-2015) at the National Institutes of Health (NIH; NCT01386437). Hepatology consultation assessed hepatic and autoimmune biomarkers and liver ultrasound in all patients. Liver biopsies evaluated autoimmune features and fibrosis. The 16S ribosomal RNA (rRNA) sequencing was performed in 35 patients' stools (12 with and 23 without APAH). Among 43 evaluable patients, 18 (42%) had APAH; in 33.3% of those with APAH, APAH occurred before developing classic APECED diagnostic criteria. At APAH diagnosis, the median age was 7.8 years, and patients manifested with aminotransferase elevation and/or hyperbilirubinemia. All patients with APAH were in clinical remission during their NIH evaluation while receiving immunomodulatory treatment. We found no difference in age, sex, or prevalence of CMC, AI, or HP between patients with or without APAH. Autoantibody positivity against aromatic L-amino acid decarboxylase, cytochrome P450 family 1 subfamily A member 2, histidine decarboxylase (HDC), bactericidal/permeability-increasing fold-containing B1, tryptophan hydroxlase, and 21-hydroxylase (21-OH), and the homozygous c.967_979del13 AIRE mutation were associated with APAH development. Classical serological biomarkers of autoimmune hepatitis (AIH) were only sporadically positive. AIH-like lymphoplasmacytic inflammation with mild fibrosis was the predominant histological feature. Stool microbiome analysis found Slackia and Acidaminococcus in greater abundance in patients with APAH.
Conclusions:
APAH is more common than previously described, may present early before classic APECED manifestations, and most often manifests with milder, treatment-responsive disease. Several APECED-associated autoantibodies, but not standard AIH-associated biomarkers, correlate with APAH.
Insights
APECED-associated hepatitis (APAH) is more common than previously thought and can appear before other APECED symptoms. This condition often presents mildly and responds well to treatment, with specific autoantibodies correlating to its development.
Area of Science:
- Endocrinology
- Hepatology
- Immunology
Background:
- Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is caused by AIRE mutations, leading to chronic mucocutaneous candidiasis and multisystem autoimmunity.
- APECED-associated hepatitis (APAH) has a previously reported prevalence of ~10% in European cohorts, with varied clinical presentations.
- This study aimed to characterize APAH in a large APECED cohort from the Americas.
Purpose of the Study:
- To determine the prevalence and clinical characteristics of APAH in an American APECED cohort.
- To identify factors associated with the development of APAH.
- To compare APAH presentation with classic autoimmune hepatitis (AIH).
Main Methods:
- Evaluation of 45 consecutive APECED patients, including hepatology consultation, liver ultrasound, and liver biopsies.
- Assessment of hepatic and autoimmune biomarkers.
- 16S ribosomal RNA (rRNA) sequencing of stool samples from 35 patients (12 with APAH, 23 without).
Main Results:
- APAH was identified in 18 out of 43 (42%) evaluable patients, with 33.3% presenting before classic APECED criteria.
- Patients with APAH showed elevated aminotransferases and/or hyperbilirubinemia, with all in clinical remission during evaluation.
- APAH development was associated with specific autoantibodies and the homozygous c.967_979del13 AIRE mutation; stool analysis revealed higher abundance of Slackia and Acidaminococcus in APAH patients.
Conclusions:
- APAH is more prevalent than previously reported and can precede other APECED manifestations.
- APAH typically presents with milder, treatment-responsive disease compared to fulminant hepatic failure.
- Specific APECED-associated autoantibodies correlate with APAH, unlike standard AIH biomarkers.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Collaborative Care
Assessment:

